• AIGEN Sciences

  Participated · Equity · Oct 2024

  AIGEN Sciences is an AI-driven drug discovery platform that develops small-molecule synthetic drugs targeting intractable diseases with high unmet medical needs. Founded in April 2021 and based in Seoul, the company provides drug research and development services using a proprietary AI platform. Its pipeline includes multiple lead substance optimizations and preclinical candidates. AIGEN aims to advance state-of-the-art AI drug discovery technologies and to transform high-cost, low-efficiency drug discovery into faster, more efficient processes. The company will use the funding to enhance its drug development capabilities and accelerate growth.

• MiNDCAFE

  Participated · Series B · Feb 2022

  Atommerce operates MiNDCAFE, a mobile app connecting users with mental health professionals via virtual therapy and an employer-focused mental health benefits (EAP) solution. The company also offers an AI chatbot, RONI, launched in December, which supports human professionals by recommending answers and is part of an ecosystem linking patients, experts and AI. With over 1 million app users in South Korea, roughly 100 enterprise clients (including Naver, NHN, Shinhan Investment, Neowiz and Seoul Metropolitan Government), about 200,000 employees using the app via EAPs, and more than 250 specialists, Atommerce has significant traction. Its revenue grew about 1,200% in Q1 2021 versus Q1 2020, and sales have risen an average of 400% annually over the past two years. The company plans to enhance its AI and machine-learning capabilities, invest in digital therapeutics, increase headcount, and expand internationally to Japan in H1 2022 and North America by year-end. Atommerce was founded in 2015 and is headquartered in Seoul.

• Dable

  Participated · Series C · Jan 2021

  Dable uses big data and machine learning to power personalized content recommendations and native-ad products for publishers. Its product suite includes Dable News for article recommendations, Dable Native Ad that integrates ad networks, and karamel.ai for e-commerce ad targeting and product recommendations. Launched in South Korea five years ago, Dable serves more than 2,500 media outlets across six Asian markets and operates subsidiaries in Taiwan and Indonesia (Taiwan accounts for 70% of overseas sales). The company reports monthly reach of 540 million unique users, five billion recommended pieces of content and over 100 million clicks, and it recorded $27.5 million in sales in 2020 with an average annual sales growth since founding of more than 50%. Dable plans accelerated international expansion — six additional Asian markets in 2021 followed by Europe and the U.S. — and aims to be the most utilized personalized recommendation platform in at least 30 countries by 2024. It also intends to launch a content management system (CMS) next year as part of a shift toward becoming a broader media tech company.

• ExoCoBio

  Participated · Series B · Sep 2018

  ExoCoBio develops exosome-based regenerative aesthetic products and brands. Founded in 2017 and led by CEO Byong Cho, the company has launched ASCE+™, EXOMAGE™, and CELLTWEET™. Those brands target skin rejuvenation, skin immune-modulation, and scalp rejuvenation. The company raised $9.3m in Series C and pre-IPO funding and has cumulatively raised about $56.3m since founding. ExoCoBio has established a strategic alliance with BENEV Company Inc., an FDA-registered medical aesthetic manufacturer in Orange County, California, to support U.S. market activities. The financing is positioned to support continued commercialization of its exosome product lines and near-term growth initiatives. ExoCoBio Inc. is a pharmaceutical R&D and cosmeceutical company developing exosome-based products. The company produces exosome pharmaceuticals and has launched cosmeceutical brands and products such as EXOMAGE™, Celltweet™ and ASCE+™. ExoCoBio works with exosomes—nano-vesicles secreted by cells that contain physiologically active substances and can stimulate cellular or tissue regeneration, with applications in skin and hair. The company plans to use recent funding to set up GMP-compliant exosome manufacturing facilities, hire talent, and secure additional commercialization opportunities in the cosmetics industry. Financially, ExoCoBio raised approximately $26.7M in a Series B and has raised about $46M cumulatively, including an $11M Series A in April 2017. The company was established in January 2017 and is led by CEO Byong Cho.

No current team members are available.